Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC)

Raushan Kurmasheva, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher, Stephen W. Erickson, John M. Maris, Yael P. Mosse, Kateryna Krytska, David Groff, Matthew Tang, Yifei Wang, Brad St. Croix, Richard Gorlick, Peter J. Houghton

Mol Cancer Ther (2019) 18 (12_Supplement): C003.

https://doi.org/10.1158/1535-7163.TARG-19-C003

Published: 01 December 2019

View articletitled, Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC)

Journal Articles

Abstract LB-B15: Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan

Peter J. Houghton, Raushan T. Kurmasheva, Richard Gorlick, E. Anders Kolb, Yael P. Mosse, Stephen W. Erickson, Yuelong Guo, Beverly A. Teicher, Malcolm A. Smith, John M. Maris

Mol Cancer Ther (2018) 17 (1_Supplement): LB-B15.

https://doi.org/10.1158/1535-7163.TARG-17-LB-B15

Published: 01 January 2018

View articletitled, Abstract LB-B15: Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan

Journal Articles

Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)

Beverly A. Teicher, Richard B. Lock, Jerry M. Collins, Richard Gorlick, E. Anders Kolb, Peter J. Houghton, Raushan T. Kurmasheva, Xiao-Nan Li, Stephen W. Erickson, Yuelong Guo, Kathryn Evans, Lin Qi, Malcolm A. Smith

Mol Cancer Ther (2018) 17 (1_Supplement): LB-B12.

https://doi.org/10.1158/1535-7163.TARG-17-LB-B12

Published: 01 January 2018

View articletitled, Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)

Journal Articles

Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib

Kristina A. Cole, Peter J. Houghton, Raushan T. Kurmasheva, Richard Gorlick, E. Anders Kolb, Min Kang, C. Patrick Reynolds, Xiao-Nan Li, Holly Lindsay, Stephen W. Erickson, Yuelong Guo, Beverly A. Teicher, Malcolm A. Smith, John M. Maris

Mol Cancer Ther (2018) 17 (1_Supplement): LB-B13.

https://doi.org/10.1158/1535-7163.TARG-17-LB-B13

Published: 01 January 2018

View articletitled, Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib

Journal Articles

Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).

C. Patrick Reynolds, Min H. Kang, Hernan Carol, Richard B. Lock, Richard Gorlick, E. Anders Kolb, Denise Alexander, Raushan T. Kurmasheva, Stephen T. Keir, John M. Maris, Jianrong Wu, Peter J. Houghton, Malcolm A. Smith

Mol Cancer Ther (2011) 10 (11_Supplement): C106.

https://doi.org/10.1158/1535-7163.TARG-11-C106

Published: 12 November 2011

View articletitled, Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).

Journal Articles

Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.

Peter J. Houghton, John M. Maris, Stephen T. Keir, Richard B. Lock, Hernan Carol, Richard Gorlick, E. Anders Kolb, Min H. Kang, C. Patrick Reynolds, Raushan T. Kurmasheva, Kathleen R. Whiteman, Malcolm Anders Smith

Mol Cancer Ther (2011) 10 (11_Supplement): C105.

https://doi.org/10.1158/1535-7163.TARG-11-C105

Published: 12 November 2011

View articletitled, Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.

Journal Articles

Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.

Malcolm A. Smith, Min H. Kang, Christopher Patrick Reynolds, Richard B. Lock, Hernan Carol, Richard Gorlick, E. Anders Kolb, John M. Maris, Stephen T. Keir, Catherine A. Billups, Raushan T. Kurmasheva, Peter J. Houghton

Mol Cancer Ther (2011) 10 (11_Supplement): C103.

https://doi.org/10.1158/1535-7163.TARG-11-C103

Published: 12 November 2011

View articletitled, Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.

Journal Articles

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

Peter J. Houghton, Christopher L. Morton, Richard Gorlick, Richard B. Lock, Hernan Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, Jianrong Wu, Amy W. Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith

Mol Cancer Ther (2010) 9 (1): 101–112.

https://doi.org/10.1158/1535-7163.MCT-09-0952

Published: 12 January 2010

View articletitled, Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

Includes: Supplementary data

Journal Articles

Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase

Peter J. Houghton, John M. Maris, Josh Courtright, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernan Carol, E. Anders Kolb, Richard Gorlick, Min Kang, C. Patrick Reynolds, Christopher L. Morton, Malcolm A. Smith

Mol Cancer Ther (2009) 8 (12_Supplement): C57.

https://doi.org/10.1158/1535-7163.TARG-09-C57

Published: 10 December 2009

View articletitled, Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC)

Abstract LB-B15: Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan

Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)

Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib

Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).

Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.

Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only